MedPath

Required and undesired effects of gender affirming hormone therapy in people with gender dysphoria: a longitudinal cohort study

Conditions
F64.0
F64.2
Transsexualism
Gender identity disorder of childhood
Registration Number
DRKS00025399
Lead Sponsor
Medizinische Klinik 1, Schwerpunkt Endokrinologie-Diabetologie Universitätsklinikum Frankfurt
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
45
Inclusion Criteria

confirmed diagnosis of gender dysphoria
- referral of a trained mental health professional, attesting indication for gender affirming hormone therapy

Exclusion Criteria

- medical history of a relevant liver disease

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Development of liver pathology as side effect of gender affirming hormone therapy.
Secondary Outcome Measures
NameTimeMethod
- cardiovascular and metabolic risk factors<br>- alteration of immunological parameters<br>- erythrocytosis under virilizing treatment<br>- alterations of body composition, muscularity and fitness<br>- subjective alterations of body perception, sexuality and muscularity
© Copyright 2025. All Rights Reserved by MedPath